Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to $23.5 million.

  • Keros Therapeutics' Non-Current Assets fell 13.77% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year decrease of 13.77%. This contributed to the annual value of $27.0 million for FY2024, which is 18.74% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Non-Current Assets is $23.5 million, which was down 3.62% from $24.4 million recorded in Q2 2025.
  • Keros Therapeutics' 5-year Non-Current Assets high stood at $27.2 million for Q3 2024, and its period low was $1.7 million during Q1 2021.
  • Over the past 3 years, Keros Therapeutics' median Non-Current Assets value was $22.7 million (recorded in 2023), while the average stood at $23.7 million.
  • In the last 5 years, Keros Therapeutics' Non-Current Assets decreased by 14.86% in 2021 and then spiked by 466.39% in 2023.
  • Keros Therapeutics' Non-Current Assets (Quarterly) stood at $3.8 million in 2021, then surged by 451.40% to $21.0 million in 2022, then rose by 8.18% to $22.7 million in 2023, then increased by 18.74% to $27.0 million in 2024, then declined by 13.77% to $23.5 million in 2025.
  • Its last three reported values are $23.5 million in Q3 2025, $24.4 million for Q2 2025, and $25.1 million during Q1 2025.